Matthew Pauls - 02 Jul 2025 Form 4 Insider Report for Pelthos Therapeutics Inc. (CHRO)

Reporting relationship: Director
Issuer ticker: CHRO
Reported as of: 02 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Jul 2025, 21:45:34 UTC
Prior SEC filing: 07 Jul 2025
Next SEC filing: 11 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Matthew Pauls

Key filing fact

Matthew Pauls filed Form 4 for Pelthos Therapeutics Inc. (CHRO) on 07 Jul 2025.

Key facts

This page summarizes Matthew Pauls's Form 4 filing for Pelthos Therapeutics Inc. (CHRO).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 07 Jul 2025, 21:45.

Change

Previous filing in this sequence was filed on 07 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001573429 Primary reporting owner

Pauls Matthew

Relationship: Director
Address: C/O PELTHOS THERAPEUTICS INC., 4020 STIRRUP CREEK DRIVE, SUITE 110, DURHAM
Signature: /s/ Matthew Pauls
Signature date: 07 Jul 2025

This filing has been restated. Open the amended filing.

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PTHS transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +25,478
Change %
Price
Shares after: 25,478
Date: 02 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,478
Exercise price: $13.50
Footnotes: F1

PTHS transaction Derivative

Stock Option

Award

Transaction value
Shares: +77,640
Change %
Price
Shares after: 77,640
Date: 02 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 77,640
Exercise price: $13.50
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 25,478 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2025, and in equal installments on a quarterly basis thereafter over a period of two (2) years.

Footnote F2

On July 2, 2025, the Reporting Person was granted stock options to purchase 77,640 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2025, and in equal installments on a quarterly basis thereafter over a period of two (2) years.